Addition of Docetaxel to Radiotherapy and ADT in Nonmetastatic Unfavorable-Risk Prostate Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Anthony V. D’Amico, MD, PhD, and colleagues found that the addition of docetaxel to radiotherapy and androgen-deprivation therapy (ADT) did not improve overall survival in nonmetastatic, unfavorable-risk prostate cancer. However, patients receiving docetaxel had a reduced incidence of radiotherapy-induced cancers, and a potential survival benefit was observed among those with a prostate-specific antigen (PSA) level < 4 ng/mL, reflecting a reduction in prostate cancer–specific mortality.
As stated by the investigators, “Although docetaxel is not recommended when managing men with unfavorable-risk prostate cancer, given negative or inconclusive results from previous randomized trials, unstudied benefits may exist.”
Study Details
The investigator-initiated study included 350 men with T1c-4N0M0 unfavorable-risk disease from sites in the United States, Australia, and New Zealand. They were randomly assigned between September 2005 and January 2015 to receive 6 months of radiotherapy and ADT with (n = 175) or without (n = 175) docetaxel at 60 mg/m2 once every 3 weeks for three cycles before radiotherapy and 20 mg/m2 once weekly during radiotherapy.
The current report includes analyses of the primary endpoint of overall survival, incidence of radiotherapy-induced cancers, and treatment effect on overall survival according to PSA subgroups.
Key Findings
After a median follow-up of 10.2 years, 89 men (25.4%) had died (44 in docetaxel group vs 45 in control group); of these, 42 (47.2%) died from prostate cancer (22 vs 20). The hazard ratio for overall survival for the docetaxel vs control group was 0.99 (95% confidence interval [CI] = 0.65–1.51, P = .98), with 10-year estimates of 72% (95% CI = 63%–79%) vs 74% (95% CI = 66%–80%). Restricted mean survival time over 10 years was 9.11 vs 8.82 years (difference = 0.29%, 95% CI = –0.19 to 0.76, P = .22).
Radiotherapy-induced cancers occurred in one patient in the docetaxel group vs eight in the control group (including 4 fatalities), yielding an age-adjusted hazard ratio of 0.13 (95% CI = 0.02–0.97, P = .046). The 10-year cumulative incidence estimates were 0.61% (95% CI = 0.06%–3.09%) vs 4.90% (95% CI = 2.13%–9.40%), yielding an observed difference of 4.29% (95% CI = 0.51%–8.07%).
In analysis adjusting for age, percent biopsies, Gleason score, and tumor category, the adjusted hazard ratio for overall survival among the docetaxel group vs control group patients with PSA < 4 ng/mL (n = 27) was 0.27 (95% CI = 0.05–1.34), whereas the adjusted hazard ratio among men with a PSA of 4 to 20 ng/mL was 1.51 (95% CI = 0.86–2.67), with P = .05 for the interaction. The improved overall survival among men with PSA < 4 ng/mL was driven by lower prostate cancer–specific mortality in the docetaxel group (0 of 14 patients = 0%) vs the control group (4 of 14 patients = 28.6%).
The investigators concluded, “Adding docetaxel to ADT and radiotherapy did not prolong overall survival in men with unfavorable-risk prostate cancer, but decreased radiotherapy-induced cancer incidence, and may prolong overall survival in the subgroup of men with a PSA < 4 ng/mL by reducing prostate cancer–specific mortality.”
Dr. D’Amico, of the Department of Radiation Oncology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, is the corresponding author for the Journal of Clinical Oncology article.
Disclosure: The study was supported by Sanofi and AstraZeneca. For full disclosures of the study authors, visit ascopubs.org.